The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evaluating pirtobrutinib for patients with R/R MZL exposed to BTKis: BRUIN cohort data
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, discusses cohort data from the BRUIN trial (NCT03740529), evaluating pirtobrutinib activity in relapsed/refractory marginal zone lymphoma (MZL). Dr Patel highlights that the strength of the BRUIN data lies in its focus on MZL, making it the strongest data available for patients with prior exposure to covalent BTK inhibitor (BTKi) therapy. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so marginal zone lymphoma is often a disease where most of our therapies are inferred from trials in follicular lymphoma. So to really have data specific to that population of patients and in a specific scenario after prior covalent BTK inhibitor, I think, really is unique. And so for me, personally, I think that the strength of that data is that it is really focused on marginal zone lymphoma...
Yeah, so marginal zone lymphoma is often a disease where most of our therapies are inferred from trials in follicular lymphoma. So to really have data specific to that population of patients and in a specific scenario after prior covalent BTK inhibitor, I think, really is unique. And so for me, personally, I think that the strength of that data is that it is really focused on marginal zone lymphoma. And so my own sequencing approach really is after a covalent BTK inhibitor, which I use quite commonly in marginal zone lymphoma, I think the data for pirtobrutinib is the strongest we have. And certainly we can see now we have CAR T-cells available as well in marginal zone lymphoma. But the population of patients enrolled in those trials is a little bit different. So I think for a patient who’s already had covalent BTK inhibitor, the strongest data we have really comes from that BRUIN experience.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
